Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2693
http://purl.obolibrary.org/obo/NCIT_C2693
|
|---|---|
| Preferred Name | Erlotinib Hydrochloride |
| Definitions |
The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. |
|---|---|
| prefLabel | Erlotinib Hydrochloride
|
| label | Erlotinib Hydrochloride
|
| CHEBI_ID | CHEBI:53509
|
| PDQ_Closed_Trial_Search_ID | 38428
|
| code | C2693
|
| Has_Target | |
| prefixIRI | NCIT:C2693
|
| in_subset |
See more
See less
|
| Display_Name | Erlotinib Hydrochloride
|
| Preferred_Name | Erlotinib Hydrochloride
|
| FDA_UNII_Code | DA87705X9K
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C22H23N3O4.HCl
|
| Maps_To | Erlotinib Hydrochloride
|
| CAS_Registry | 183319-69-9
|
| NSC Number | 718781
|
| NCI_Drug_Dictionary_ID | 38428
|
| Legacy Concept Name | Erlotinib
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| ALT_DEFINITION | A drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib hydrochloride is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38428
|
| Accepted_Therapeutic_Use_For | Malignant glioma; Locally advanced or metastic non-small cell lung carcinoma; Locally advanced, unresectable or metastatic pancreatic carcinoma
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1533491
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |